Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Vekemans

Showing results (51-60 of 115) with videos related to

Pageof 12
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|January 5, 2002
Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccinationMartin O C Ota, Johan Vekemans, Susanna E Schlegel-Haueter, et al.
Plos One|November 17, 2010
Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trialPedro Aide, John J Aponte, Montse Renom, et al.
Plos One|October 28, 2009
A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in GabonBertrand Lell, Selidji Agnandji, Isabelle von Glasenapp, et al.
Malaria Journal|November 24, 2020
Building momentum for malaria vaccine research and development: key considerationsChetan E Chitnis, David Schellenberg, Johan Vekemans, et al.
Malaria Journal|August 6, 2011
Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient careJohan Vekemans, Kevin Marsh, Brian Greenwood, et al.
Malaria Journal|April 18, 2015
The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infantsAnthony Ajua, Bertrand Lell, Selidji Todagbe Agnandji, et al.
The Lancet. Infectious Diseases|January 27, 2019
Serocorrelates of protection against infant group B streptococcus diseaseKirsty Le Doare, Beate Kampmann, Johan Vekemans, et al.
Vaccine|March 30, 2011
Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trialPedro Aide, Carlota Dobaño, Jahit Sacarlal, et al.
Malaria Journal|January 10, 2013
Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic regionSalim Abdulla, Nahya Salim, Francisca Machera, et al.
The Journal of Infectious Diseases|December 4, 2012
Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implicationsAmed Ouattara, Shannon Takala-Harrison, Mahamadou A Thera, et al.
Pageof 12

Showing results (51-60 of 115) with videos related to

Sort By:
Pageof 12
Journal of Immunology (Baltimore, Md. : 1950)|January 5, 2002
Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccinationMartin O C Ota, Johan Vekemans, Susanna E Schlegel-Haueter, et al.
Plos One|November 17, 2010
Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trialPedro Aide, John J Aponte, Montse Renom, et al.
Plos One|October 28, 2009
A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in GabonBertrand Lell, Selidji Agnandji, Isabelle von Glasenapp, et al.
Malaria Journal|November 24, 2020
Building momentum for malaria vaccine research and development: key considerationsChetan E Chitnis, David Schellenberg, Johan Vekemans, et al.
Malaria Journal|August 6, 2011
Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient careJohan Vekemans, Kevin Marsh, Brian Greenwood, et al.
Malaria Journal|April 18, 2015
The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infantsAnthony Ajua, Bertrand Lell, Selidji Todagbe Agnandji, et al.
The Lancet. Infectious Diseases|January 27, 2019
Serocorrelates of protection against infant group B streptococcus diseaseKirsty Le Doare, Beate Kampmann, Johan Vekemans, et al.
Vaccine|March 30, 2011
Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trialPedro Aide, Carlota Dobaño, Jahit Sacarlal, et al.
Malaria Journal|January 10, 2013
Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic regionSalim Abdulla, Nahya Salim, Francisca Machera, et al.
The Journal of Infectious Diseases|December 4, 2012
Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implicationsAmed Ouattara, Shannon Takala-Harrison, Mahamadou A Thera, et al.
Pageof 12